[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610349":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":27,"locations":33,"responsibleParty":98,"collaborators":11,"id":100,"slug":101,"hasResults":102,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":11,"eligibilityCriteria":106,"healthyVolunteers":102,"sex":107,"minAge":108,"maxAge":11,"enrollmentInfo":109,"targetDuration":11,"studyType":112,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"Stemline Therapeutics, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A: MEN2501 Dose Escalation","EXPERIMENTAL",null,[13],"Drug: MEN2501",{"label":15,"type":10,"description":11,"interventionNames":16},"Part B: MEN2501 Dose Expansion & Optimization",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","MEN2501","Oral tablet",[9,15],[24],{"name":25,"affiliation":5,"role":26},"Medical Director","STUDY_DIRECTOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Stemline Trials","CONTACT","1-877-332-7961","cwilliams@menarinistemline.com; MEN2501_StudyTeam@menarinistemline.com",[34,48,58,68,78,88],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":11},"Highlands Oncology Group","RECRUITING","Springdale","Arkansas","72762","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-94.12881,36.18674,{"lat":46,"lon":45},{"facility":49,"status":36,"city":50,"state":51,"zip":52,"country":40,"countryCode":41,"cosmosGeoPoint":53,"geoPoint":57,"contacts":11},"Yale University","New Haven","Connecticut","06519",{"type":43,"coordinates":54},[55,56],-72.92816,41.30815,{"lat":56,"lon":55},{"facility":59,"status":36,"city":60,"state":61,"zip":62,"country":40,"countryCode":41,"cosmosGeoPoint":63,"geoPoint":67,"contacts":11},"Florida Cancer Specialists & Research Institute","Sarasota","Florida","34232",{"type":43,"coordinates":64},[65,66],-82.53065,27.33643,{"lat":66,"lon":65},{"facility":69,"status":36,"city":70,"state":71,"zip":72,"country":40,"countryCode":41,"cosmosGeoPoint":73,"geoPoint":77,"contacts":11},"Karmanos Cancer Institute","Detroit","Michigan","48201",{"type":43,"coordinates":74},[75,76],-83.04575,42.33143,{"lat":76,"lon":75},{"facility":79,"status":36,"city":80,"state":81,"zip":82,"country":40,"countryCode":41,"cosmosGeoPoint":83,"geoPoint":87,"contacts":11},"Mayo Clinic","Rochester","Minnesota","55905",{"type":43,"coordinates":84},[85,86],-92.4699,44.02163,{"lat":86,"lon":85},{"facility":89,"status":36,"city":90,"state":91,"zip":92,"country":40,"countryCode":41,"cosmosGeoPoint":93,"geoPoint":97,"contacts":11},"NEXT Virginia","Fairfax","Virginia","22031",{"type":43,"coordinates":94},[95,96],-77.30637,38.84622,{"lat":96,"lon":95},{"type":99,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100610349","phase-1-a-first-in-human-study-of-men2501-in-participants-with-platinum-resistant-ovarian-cancer-100610349",false,"NCT07226427","A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer","A Phase 1, First-in-Human Study of MEN2501, a KIF18A Inhibitor, as Monotherapy in Participants With Platinum-Resistant Ovarian Cancer","Key Inclusion Criteria:\n\n* Participants must have a histopathologically confirmed diagnosis of high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.\n\nKey Exclusion Criteria:\n\n* Participants with primary platinum-refractory disease.\n\nNote: Other protocol-defined inclusion\u002Fexclusion criteria may apply.","FEMALE","18 Years",{"count":110,"type":111},100,"ESTIMATED","INTERVENTIONAL",[114],"PHASE1","This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.",[117],"Platinum-resistant Ovarian Cancer",[20,119,120],"First-in-Human","Ovarian Cancer","2026-05-20",{"date":123,"type":124},"2026-05-26","ACTUAL",{"date":126,"type":124},"2026-01-10",{"date":128,"type":111},"2028-06-02",{"name":5,"class":6},6]